Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Women's Health
Published in: BMC Women's Health 1/2014

Open Access 01-12-2014 | Research article

“If you can’t treat HPV, why test for it?” Women’s attitudes to the changing face of cervical cancer prevention: a focus group study

Authors: Judith McRae, Cara Martin, John O’Leary, Linda Sharp

Published in: BMC Women's Health | Issue 1/2014

Login to get access

Abstract

Background

The relationship between infection with high-risk strains of human papillomavirus (HPV) and cervical cancer is transforming prevention through HPV vaccination and HPV oncogenic testing. In Ireland, a national cervical cancer screening programme and HPV vaccination were recently launched; HPV testing is currently being integrated into the screening programme. Women’s views on the transformation of cervical cancer prevention have been relatively little investigated.

Methods

Using qualitative focus groups, we determined women’s knowledge, attitudes towards, and acceptability of cervical cancer screening, HPV oncogenic testing and vaccination of HPV. Fifty nine women, recruited through primary care in Ireland, participated in ten focus groups. A dynamic topic guide was developed from literature reviewed. Women were provided with standardised information about HPV infection, HPV testing. Discussion transcripts were analysed thematically.

Results

The primary themes that emerged regarding HPV infection were: knowledge, emotional response and societal influences; especially those of healthcare practitioners. Knowledge, logistics, and psychological impact were the primary themes relating to HPV testing. Women’s attitudes towards HPV testing changed during discussion as issues were explored, thus demonstrating the complexity of this issue; lack of existing treatment for HPV infection influenced women’s attitudes, attachment to existing cervical cancer screening also was a significant factor.

Conclusions

Women currently have a strong attachment to cytology and any changes towards HPV primary testing will need to be managed carefully. To ensure that future cervical cancer prevention strategies will be acceptable to women, sufficient thought will have to be given to information provision and education. We identified the importance to women of healthcare practitioners’ opinions regarding HPV. Appropriate and timely information on HPV will be crucial in order to minimise possible psychological effects women may have.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
5.
6.
7.
Harper DM, Williams KB: Prophylactic HPV vaccines: current knowledge of impact on gynaecologic premalignancies. Discov Med. 2010, 10 (50): 7-17.PubMed
8.
Harper DM, Nieminen P, Paavonen J, Lehtinen M: Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect Dis. 2010, 10 (9): 594-595. 10.1016/S1473-3099(10)70182-1.CrossRefPubMed
9.
10.
11.
Peto J, Gilham C, Fletcher O, Matthews F: The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004, 364 (9430): 249-256. 10.1016/S0140-6736(04)16674-9.CrossRefPubMed
12.
13.
Malterud K: Qualitative research: standard, challenges and guidelines. Lancet. 2001, 358: 483-488. 10.1016/S0140-6736(01)05627-6.CrossRefPubMed
14.
Knodel J: The Design and Analysis of Focus Group Studies: A Practical Approach. Successful focus groups: advancing the state of the art. Edited by: Morgan D. 1993, Newbury Park, California: Sage
15.
Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ: Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008, 26 (Suppl 10): K29-K41.CrossRefPubMed
16.
Franceschi S, Denny L, Irwin KL, Jeronimo J, Lopalco PL, Monsonego J, Peto J, Ronco G, Sasieni P, Wheeler CM: Eurogin 2010 roadmap on cervical cancer prevention. Int J Cancer. 2011, 128 (12): 2765-2774. 10.1002/ijc.25915.CrossRefPubMed
17.
Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE: Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011, 103 (5): 368-383. 10.1093/jnci/djq562.CrossRefPubMedPubMedCentral
18.
Mahoney D: Reducing pap test frequency may be a hard sell. Internal Med News. 2003, 37 (3): 203-208. Ann. Fam. Med. 2003:1[4]
19.
Dieng M, Trevena L, Turner RM, Wadolowski M, McCaffery K: What Australian women want and when they want it: cervical screening testing preferences, decision-making styles and information needs. Health Expect. 2011, doi: 10.1111/j.1369-7625.2011.00707.x
20.
Lancucki L, Fender M, Koukari A, Lynge E, Mai V, Mancini E, Onysko J, Ronco G, Tornberg S, Vessey M, Patnick J: A fall-off in cervical screening coverage of younger women in developed countries. J Med Screen. 2010, 17 (2): 91-96. 10.1258/jms.2010.010017.CrossRefPubMed
21.
Cook C: About as comfortable as a stranger putting their finger up your nose’: speculation about the (extra)ordinary in gynaecological examinations’. Cult Health Sex. 2011, 13 (7): 767-780. 10.1080/13691058.2011.577906.CrossRefPubMed
22.
Kwok C, White K, Roydhouse JK: Chinese-Australian Women’s Knowledge, Facilitators and Barriers Related to Cervical Cancer Screening: a qualitative study. J Immigr Minor Health. 2011, 13 (6): 1076-1083. 10.1007/s10903-011-9491-4.CrossRefPubMed
23.
McSherry L, Dombrowski S, Francis J, Murphy J, Martin C, O’Leary J, Sharp L: for the ATHENS Group. “It’s a can of worms”: understanding primary care practitioners’ behaviours in relation to HPV using the Theoretical Domains Framework. Implementation. Science. 2012, 7: 73.
24.
Jain N, Irwin KL, Montano D, Kasprzyk D, Carlin L, Freeman C, Barnes R, Christian J, Wolters C: Family physicians’ knowledge of genital human papillomavirus (HPV) infection and HPV-related conditions, United States, 2004. Fam Med. 2006, 38 (7): 483-489.PubMed
25.
Murphy J, Sharp L, Carsin AE: Attitudes and knowledge of GP’s towards Human Papillomavirus infection, testing and vaccination: results from a national survey in Ireland. J Epidemiol Comm Health. 2008, 62 (Suppl 1): A21-A22.
26.
Ramirez A, Ramos D, Clayton L, Kanowitz S, Moscicki A: Genital human papillomavirus infections: knowledge, perception of risk and actual risk in a nonclinic population of young women. J Womens Health. 1997, 6 (1): 113-121. 10.1089/jwh.1997.6.113.CrossRefPubMed
27.
Gerhardt C, Pong K, Kollar L, Hillard P, Rosenthal S: Adolescents’ knowledge of human papillomavirus and cervical dysplasia. J Pediatr Adolesc Gynecol. 2000, 13 (1): 15-20. 10.1016/S1083-3188(99)00031-5.CrossRefPubMed
28.
Lazcano-Ponce E, Rivera L, Arillo-Santillian E, Salmeron J, Hernandez-Avila M, Munoz N: Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch Med Res. 2001, 32 (3): 243-247. 10.1016/S0188-4409(01)00277-6.CrossRefPubMed
29.
Gudmundsdóttir T, Tryggvadóttir L, Allende M, Mast T, Briem H, Sigurdsson K: Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trial. Acta Obstet Gynecol Scand. 2003, 82 (4): 345-350. 10.1080/j.1600-0412.2003.00086.x.CrossRefPubMed
30.
Andersson-Ellstrom A, Milsom I: Knowledge about the prevention of sexually transmitted diseases: a longitudinal study of young women from 16–23 years of age. Sex Transm Infect. 2002, 78 (5): 339-341. 10.1136/sti.78.5.339.CrossRefPubMed
31.
Pitts M, Clarke T: Human papillomavirus infections and risks of cervical cancer: what do women know?. Health Educ Res. 2002, 17 (6): 706-714. 10.1093/her/17.6.706.CrossRefPubMed
32.
Philips Z, Johnson S, Avis M, Whynes D: Human papillomavirus and the value of screening: young women’s knowledge of cervical cancer. Health Educ Res. 2003, 18 (3): 318-328. 10.1093/her/cyf022.CrossRefPubMed
33.
Waller J, McCaffery K, Wardle J: Beliefs about the risk factors for cervical cancer in a British population sample. Prev Med. 2004, 38 (6): 745-753. 10.1016/j.ypmed.2004.01.003.CrossRefPubMed
34.
Waller J, McCaffery K, Nazroo J, Wardle J: Making sense of information about HPV in cervical screening: a qualitative study. Br J Cancer. 2005, 92 (2): 265-270.PubMedPubMedCentral
35.
Mays RM, Zimet GD, Winston Y, Kee R, Dickes J, Su L: Human papilloma virus, genital warts, pap smears, and cervical cancer: knowledge and beliefs of adolescent and adult women. Health Care Women Int. 2000, 21: 361-374. 10.1080/07399330050082218.CrossRefPubMed
36.
Marlow L, Wardle J, Grant N, Waller J: Human papillomavirus (HPV) information needs: a theoruitacal framework. J Fam Plann Reprod Health Care. 2009, 35 (1): 29-33. 10.1783/147118909787072432.CrossRefPubMedPubMedCentral
37.
McCaffery K, Waller J, Nazroo J, Wardle J: Social and psychological impact of HPV testing in cervical screening: a qualitative study. Sex Transm Infect. 2006, 82 (2): 169-174. 10.1136/sti.2005.016436.CrossRefPubMedPubMedCentral
38.
McCaffery KJ, Irwig L, Turner R, Chan S, Macaskill P, Lewicka M, Clarke J, Weisberg E, Barratt A: Psychosocial outcomes of three triage methods for the management of borderline abnormal cervical smears: an open randomised trial. BMJ. 2010, 340: b4491-10.1136/bmj.b4491.CrossRefPubMedPubMedCentral
39.
Johnson CY, Sharp L, Cotton SC, Harris C, Gray N, Little J: TOMBOLA Group. Human papillomavirus infection and anxiety: analyses in women with low-grade cervical cytological abnormalities unaware of their infection status. PLoS One. 2011, 6 (6): e21046-10.1371/journal.pone.0021046.CrossRefPubMedPubMedCentral
40.
O’Conner M, Costello L, Murphy J, Prediville W, Martin C, O’Leary J, Sharp L, on behalf of the Irish Screening Research Consortium (CERVIVA): ‘Information barriers and factors influencing information needs among women having HPV tests as part of routine follow-up for abnormal cervical cytology’. Patient Educ Couns. Awaiting publication, under review by PLOS One
41.
42.
Metadata
Title
“If you can’t treat HPV, why test for it?” Women’s attitudes to the changing face of cervical cancer prevention: a focus group study
Authors
Judith McRae
Cara Martin
John O’Leary
Linda Sharp
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2014
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/1472-6874-14-64

Other articles of this Issue 1/2014

BMC Women's Health 1/2014 Go to the issue

Research article

Predictors of HIV prevalence among street-based female sex workers in Andhra Pradesh state of India: a district-level analysis

Research article

A simple and feasible questionnaire to estimate menstrual blood loss: relationship with hematological and gynecological parameters in young women

Research article

Prevalence, impacts and medical managements of premenstrual syndrome among female students: cross-sectional study in college of health sciences, Mekelle University, Mekelle, Northern Ethiopia

Research article

A qualitative study of the background and in-hospital medicolegal response to female burn injuries in India

Research article

Awareness of Pap testing and factors associated with intent to undergo Pap testing by level of sexual experience in unmarried university students in Korea: results from an online survey

Research article

Cervical cancer knowledge and screening behaviors among female university graduates of year 2012 attending national graduate orientation program, Bhutan